CTOs on the Move

Ivenix

www.ivenix.com

 
Ivenix, Inc. is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow. The company is headquartered in Amesbury, Massachusetts.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.ivenix.com
  • 21 Water St
    Amesbury, MA USA 01913
  • Phone: 978.792.5000

Executives

Name Title Contact Details

Funding

Ivenix raised $42M on 09/01/2015

Similar Companies

Del Pilar Medical and Urgent Care Center

Del Pilar Medical and Urgent Care Center is a Mishawaka, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Integrated healthcare business solutions

Integrated healthcare business solutions is a Franklin, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Regulatory Presentation Management

Regulatory Presentation Management is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Seasons East Greenwich

Seasons East Greenwich is a East Greenwich, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.